Robert Koval, MD
Rheumatology · Austin, TXNPI 1659427334
Payments from drug & device makers
Across 1,428 payments — averaging $105.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$111K
- AbbVie$21K
- Amgen$5K
- UCB, Inc.$3K
- Aurinia Pharma U.S., Inc.$1K
- Janssen Scientific Affairs, LLC$1K
- plus $8K from 21 others
What the payments were for
- Consulting fees$4,0173%
- Speaking & faculty fees$100,08367%
- Travel & lodging$19,29513%
- Food & beverage$26,25518%
- Education$2990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 438 | $110,795 |
| AbbVie | 253 | $21,120 |
| Amgen(2 entities) | 201 | $4,687 |
| UCB, Inc. | 101 | $2,509 |
| Aurinia Pharma U.S., Inc. | 76 | $1,365 |
| Janssen Scientific Affairs, LLC | 7 | $1,213 |
| Novartis | 50 | $1,112 |
| Sanofi | 47 | $1,053 |
| Pfizer | 52 | $1,050 |
| Lilly USA, LLC | 48 | $1,046 |
| E.r. Squibb & Sons, L.L.C. | 24 | $961 |
| AstraZeneca | 25 | $647 |
| GSK | 19 | $556 |
| Boehringer Ingelheim | 19 | $388 |
| Genentech USA, Inc. | 9 | $263 |
| Sanofi-aventis U.S. LLC | 8 | $241 |
| Radius Health, Inc. | 11 | $202 |
| Cardinal Health 110 LLC | 2 | $200 |
| Mallinckrodt Hospital Products Inc. | 5 | $142 |
| Bristol Myers Squibb | 18 | $141 |
| Mallinckrodt Enterprises LLC | 3 | $60 |
| Fresenius Kabi USA, LLC | 2 | $50 |
| Actelion Pharmaceuticals US, Inc. | 4 | $45 |
| Sandoz | 2 | $35 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Alvogen Inc | 1 | $21 |
| Sobi, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,949 in reported general payments places this provider in the 80th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 88 | $754,883 |
| Humira(Cf) PenAdalimumab | 64 | $526,731 |
| Humira(Cf)Adalimumab | 40 | $354,523 |
| Xeljanz XrTofacitinib Citrate | 57 | $345,546 |
| Cimzia (2 Pack)Certolizumab Pegol | 40 | $227,105 |
| OrenciaAbatacept | 28 | $217,110 |
| KevzaraSarilumab | 37 | $177,927 |
| RinvoqUpadacitinib | 26 | $171,184 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $149,330 |
| Actemra ActpenTocilizumab | 26 | $120,226 |
| Enbrel MiniEtanercept | 14 | $99,928 |
| OtezlaApremilast | 21 | $99,444 |
| Orencia ClickjectAbatacept | 17 | $99,341 |
| HumiraAdalimumab | 12 | $78,752 |
| KineretAnakinra | 13 | $70,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq, Humira | $21,120 | $604,45878 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,509 | $227,10540 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $961 | $217,11028 claims |
| SanofiKevzara | $1,053 | $177,92737 claims |
| AmgenOtezla | $4,687 | $99,44421 claims |
| Alvogen IncTeriparatide | $21 | $22,84513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Austin
- Paul PickrellAustin$40.9M
- Anurekha ChadhaAustin$1.9M
- Tina BunchAustin$974K
- Atul SinghalMesquite$13.9M
- Shaikh AliTomball$9.8M
- Jitendra VasandaniLubbock$6.4M
- Dhiman BasuColleyville$6.2M
- Tamar BrionezThe Woodlands$5.2M
- Philip WallerHouston$4.9M
- John CushDallas$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.